Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 18;13(3):142.
doi: 10.3390/medsci13030142.

Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer

Walid Shalata  1   2 , Rashad Naamneh  2   3 , Wenad Najjar  4 , Mohnnad Asla  2 , Adam Abu Gameh  2 , Mahmoud Abu Amna  5 , Leonard Saiegh  5   6 , Abed Agbarya  5   7
Affiliations
Review

Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer

Walid Shalata et al. Med Sci (Basel). .

Abstract

Background: Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy characterized by rapid growth, early metastatic dissemination, and a dismal prognosis. For decades, treatment paradigms remained largely stagnant, particularly for extensive-stage disease (ES-SCLC). However, the last five years have witnessed a significant evolution in the therapeutic landscape.

Methods: The information for this article was gathered by synthesizing data from several key sources. This article synthesizes the evidence supporting current standards of care for both limited-stage (LS-SCLC) and ES-SCLC, incorporating data from pivotal clinical trials, a network meta-analysis of first-line chemoimmunotherapy regimens, and a critical appraisal of international treatment guidelines, and a critical analysis of international treatment guidelines from prominent organizations like the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO). This comprehensive approach allows for a robust and well-supported summary of the current therapeutic landscape.

Results: For limited-stage SCLC (LS-SCLC), concurrent chemoradiotherapy (cCRT) remains the curative-intent standard, but its efficacy is now being augmented by consolidative immunotherapy, as demonstrated by the landmark ADRIATIC trial. The role of prophylactic cranial irradiation (PCI) in LS-SCLC is being re-evaluated in the era of high-sensitivity brain imaging and concerns over neurotoxicity. For ES-SCLC, the treatment paradigm has been fundamentally transformed by the integration of immune checkpoint inhibitors (ICIs) with platinum-etoposide chemotherapy, establishing a new standard of care that offers a modest but consistent survival benefit.

Conclusions: The treatment of SCLC has been significantly advanced by the integration of immunotherapy, particularly for extensive-stage disease, which has established a new standard of care and improved patient outcomes. Looking to the future, the quest for predictive biomarkers and the development of novel therapeutic classes, such as Bi-specific T-cell Engagers (BiTEs) and antibody-drug conjugates, promise to build upon recent progress and offer new hope for improving the dismal prognosis associated with this disease.

Keywords: CASPIAN trial; IMforte; IMpower133 trial; platinum agent and etoposide; prophylactic cranial irradiation; small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 2
Figure 2
Forest plot of meta-analysis of prophylactic cranial irradiation (PCI) versus observation in limited-stage small-cell lung cancer (LS-SCLC) after response to initial therapy. The plot illustrates the hazard ratios (HRs) and 95% confidence intervals (CIs), in the left side brain metastasis-free survival (BMFS), and in the write side the overall survival (OS). The summary estimate (diamond) demonstrates a consistent and significant reduction in brain metastasis (HR < 1) and a more modest but statistically significant improvement in overall survival. Data are synthesized from representative studies included in meta-analyses [41,48].
Figure 1
Figure 1
Current management of LS-SCLC: a curative-intent treatment paradigm.
Figure 3
Figure 3
Median overall survival for current immune checkpoint inhibitors in first-line therapy for ES-SCLC.
Figure 4
Figure 4
Navigating the overall survival of relapsed or refractory extensive-stage small-cell lung cancer.
See this image and copyright information in PMC

References

    1. Smolarz B., Łukasiewicz H., Samulak D., Piekarska E., Kołaciński R., Romanowicz H. Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature) Int. J. Mol. Sci. 2025;26:2049. doi: 10.3390/ijms26052049. - DOI - PMC - PubMed
    1. Megyesfalvi Z., Gay C.M., Popper H., Pirker R., Ostoros G., Heeke S., Lang C., Hoetzenecker K., Schwendenwein A., Boettiger K., et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J. Clin. 2023;73:620–652. doi: 10.3322/caac.21785. - DOI - PubMed
    1. Rudin C.M., Brambilla E., Faivre-Finn C., Sage J. Small-cell lung cancer. Nat. Rev. Dis. Primers. 2021;7:3. doi: 10.1038/s41572-020-00235-0. - DOI - PMC - PubMed
    1. Wells L.E., Cohen S., Brennan B., Banerjee M., Kalemkerian G.P. Epidemiology of SCLC in the United States From 2000 to 2019: A Study Utilizing the Surveillance, Epidemiology, and End Results Registry. JTO Clin. Res. Rep. 2025;6:100799. doi: 10.1016/j.jtocrr.2025.100799. - DOI - PMC - PubMed
    1. Uprety D., Seaton R., Niroula A., Hadid T., Parikh K., Ruterbusch J.J. Trends in the Incidence and Survival Outcomes in Patients With Small Cell Lung Cancer in the United States: An Analysis of the SEER Database. Cancer Med. 2025;14:e70608. doi: 10.1002/cam4.70608. - DOI - PMC - PubMed

LinkOut - more resources